Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 15/20 | 0.49 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846706 | 0.79 | CSNK2A1 (0.50) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2500626 | 0.79 | P4HTM (0.56) | P4HTMP4HA1MIF | |
| SCHEMBL10487101 | 0.79 | P4HTM (0.50) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL249720 | 0.77 | P4HTM (0.59) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL31359466 | 0.77 | P4HTM (0.59) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL69566 | 0.76 | P4HTM (0.63) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL9621696 | 0.75 | P4HTM (0.57) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL21485420 | 0.75 | P4HTM (0.57) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2324574 | 0.75 | RORC (0.57) | P4HTMKDM4EALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5281904 | 0.74 | LCK (0.58) | P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| EP-1863794-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | Targegen, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006101977-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | P4HTM 3856/4885P4HA1 3798/4885MIF 3827/4885 |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | P4HTM 3318/4885P4HA1 4111/4885MIF 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.